Suppr超能文献

酒精性肝病:肠道微生物群与肝脏的相互作用

Alcoholic liver disease: the gut microbiome and liver cross talk.

作者信息

Hartmann Phillipp, Seebauer Caroline T, Schnabl Bernd

机构信息

Department of Medicine, University of California, San Diego, La Jolla, California.

出版信息

Alcohol Clin Exp Res. 2015 May;39(5):763-75. doi: 10.1111/acer.12704.

Abstract

Alcoholic liver disease (ALD) is a leading cause of morbidity and mortality worldwide. Alcoholic fatty liver disease can progress to steatohepatitis, alcoholic hepatitis, fibrosis, and cirrhosis. Patients with alcohol abuse show quantitative and qualitative changes in the composition of the intestinal microbiome. Furthermore, patients with ALD have increased intestinal permeability and elevated systemic levels of gut-derived microbial products. Maintaining eubiosis, stabilizing the mucosal gut barrier, or preventing cellular responses to microbial products protect from experimental ALD. Therefore, intestinal dysbiosis and pathological bacterial translocation appear fundamental for the pathogenesis of ALD. This review highlights causes for intestinal dysbiosis and pathological bacterial translocation, their relationship, and consequences for ALD. We also discuss how the liver affects the intestinal microbiota.

摘要

酒精性肝病(ALD)是全球发病和死亡的主要原因。酒精性脂肪性肝病可进展为脂肪性肝炎、酒精性肝炎、纤维化和肝硬化。酗酒患者的肠道微生物群组成存在数量和质量上的变化。此外,ALD患者的肠道通透性增加,肠道来源的微生物产物的全身水平升高。维持微生态平衡、稳定肠道黏膜屏障或防止细胞对微生物产物的反应可预防实验性ALD。因此,肠道生态失调和病理性细菌易位似乎是ALD发病机制的基础。本综述重点介绍了肠道生态失调和病理性细菌易位的原因、它们之间的关系以及对ALD的影响。我们还讨论了肝脏如何影响肠道微生物群。

相似文献

1
Alcoholic liver disease: the gut microbiome and liver cross talk.
Alcohol Clin Exp Res. 2015 May;39(5):763-75. doi: 10.1111/acer.12704.
3
Alcohol or Gut Microbiota: Who Is the Guilty?
Int J Mol Sci. 2019 Sep 14;20(18):4568. doi: 10.3390/ijms20184568.
4
Gut-liver axis in alcoholic liver disease.
Gastroenterology. 2015 Jan;148(1):30-6. doi: 10.1053/j.gastro.2014.10.042. Epub 2014 Nov 11.
6
Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice.
Gastroenterology. 2015 Jan;148(1):203-214.e16. doi: 10.1053/j.gastro.2014.09.014. Epub 2014 Sep 16.
7
Gut Microbiota and Complications of Liver Disease.
Gastroenterol Clin North Am. 2017 Mar;46(1):155-169. doi: 10.1016/j.gtc.2016.09.013.
8
Are Probiotics Effective in Targeting Alcoholic Liver Diseases?
Probiotics Antimicrob Proteins. 2019 Jun;11(2):335-347. doi: 10.1007/s12602-018-9419-6.
9
Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.
J Hepatol. 2017 Apr;66(4):806-815. doi: 10.1016/j.jhep.2016.11.008. Epub 2016 Nov 25.
10
Microbiome as a therapeutic target in alcohol-related liver disease.
J Hepatol. 2019 Feb;70(2):260-272. doi: 10.1016/j.jhep.2018.10.019.

引用本文的文献

1
Gut microbiome-specific nanoparticle-based therapeutics for liver diseases.
World J Gastroenterol. 2025 Jul 21;31(27):109105. doi: 10.3748/wjg.v31.i27.109105.
2
Efficacy of sclareol based on 16S rDNA sequencing in modulating gut microbiota composition in estradiol-treated mice.
Biosci Microbiota Food Health. 2025;44(3):235-244. doi: 10.12938/bmfh.2024-129. Epub 2025 May 8.
3
Effect of aging on the development and progression of alcohol-associated liver disease.
Alcohol Clin Exp Res (Hoboken). 2025 Jul;49(7):1412-1423. doi: 10.1111/acer.70086. Epub 2025 Jun 3.
5
Betaine regulates the gut-liver axis: a therapeutic approach for chronic liver diseases.
Front Nutr. 2025 Mar 24;12:1478542. doi: 10.3389/fnut.2025.1478542. eCollection 2025.
6
New insights in the pathogenesis of alcohol-related liver disease: The metabolic, immunologic, and neurologic pathways.
Liver Res. 2022 Oct 3;7(1):1-8. doi: 10.1016/j.livres.2022.09.004. eCollection 2023 Mar.
7
Small-molecule chemical probes for the potential therapeutic targets in alcoholic liver diseases.
Liver Res. 2023 Sep 12;7(3):177-188. doi: 10.1016/j.livres.2023.09.001. eCollection 2023 Sep.
10
Elafibranor alleviates alcohol-related liver fibrosis by restoring intestinal barrier function.
World J Gastroenterol. 2024 Nov 21;30(43):4660-4668. doi: 10.3748/wjg.v30.i43.4660.

本文引用的文献

1
Implication of gut microbiota in nonalcoholic fatty liver disease.
PLoS Pathog. 2015 Jan 27;11(1):e1004559. doi: 10.1371/journal.ppat.1004559. eCollection 2015 Jan.
2
Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice.
FASEB J. 2015 Mar;29(3):1043-55. doi: 10.1096/fj.14-259515. Epub 2014 Dec 2.
3
Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial.
Gastroenterology. 2014 Dec;147(6):1327-37.e3. doi: 10.1053/j.gastro.2014.08.031. Epub 2014 Aug 27.
4
Gut-liver axis in alcoholic liver disease.
Gastroenterology. 2015 Jan;148(1):30-6. doi: 10.1053/j.gastro.2014.10.042. Epub 2014 Nov 11.
5
Human genetics shape the gut microbiome.
Cell. 2014 Nov 6;159(4):789-99. doi: 10.1016/j.cell.2014.09.053.
6
Ethanol and liver: recent insights into the mechanisms of ethanol-induced fatty liver.
World J Gastroenterol. 2014 Oct 28;20(40):14672-85. doi: 10.3748/wjg.v20.i40.14672.
7
Postbiotic activities of lactobacilli-derived factors.
J Clin Gastroenterol. 2014 Nov-Dec;48 Suppl 1:S18-22. doi: 10.1097/MCG.0000000000000231.
8
Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity.
Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):E4485-93. doi: 10.1073/pnas.1415174111. Epub 2014 Oct 6.
9
Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function.
Am J Physiol Gastrointest Liver Physiol. 2014 Nov 15;307(10):G951-7. doi: 10.1152/ajpgi.00268.2014. Epub 2014 Sep 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验